Update: The Pathogenesis and Treatment of Polycystic Ovary Syndrome

The document from July 2003 provides an update on Polycystic Ovary Syndrome (PCOS), affecting 5% to 10% of women of reproductive age, characterized by a range of symptoms due to increased androgen production, menstrual irregularities, and insulin resistance. The pathogenesis is believed to be multifactorial with potential genetic contributions. Diagnosis is complex and largely exclusionary, relying on symptoms and ruling out other conditions. Treatment focuses on symptom management, including androgen reduction, menstrual regulation, weight loss, and fertility restoration. Clomiphene citrate is the standard for ovulation induction, while metformin shows promise for various PCOS-related issues, though its effectiveness in lean women and impact on live birth rates require further research. The document emphasizes the need for more studies to understand PCOS progression and treatment, noting that Nurse Practitioners can manage most PCOS-related health issues.